LDL-Apheresis Removes Serum Amyloid P and A in Hypercholesterolemic Patients

Palumbo, Barbara; Cardinali, Laura; Sinzinger, H.

doi:10.1016/s0049-3848(99)00206-6

Cited by 8 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SAA is an acute phase protein, present in HDL in several isoforms 45 that has been associated with atherosclerotic disease [46], and from previous studies it is known that lipoprotein apheresis reduces serum amyloid A and serum amyloid P [47]. However, in the present study we only find a non-significant reduction in SAA1 during apheresis.…”

Section: Cec Pon1 Activity and Saa1contrasting

confidence: 81%

Lipoprotein apheresis affects lipoprotein particle subclasses more efficiently compared to the PCSK9 inhibitor evolocumab, a pilot study

Lappegård

Kjellmo

Ljunggren

et al. 2018

Transfusion and Apheresis Science

View full text Add to dashboard Cite

Lipoprotein apheresis and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are last therapeutic resorts in patients with familial hypercholesterolemia (FH). We explored changes in lipoprotein subclasses and high-density lipoprotein (HDL) function when changing treatment from lipoprotein apheresis to PCSK9 inhibition. We measured the levels of low-density lipoprotein (LDL) and HDL particle subclasses, serum amyloid A1 (SAA1), paraoxonase-1 (PON1) activity and cholesterol efflux capacity (CEC) in three heterozygous FH patients. Concentrations of all LDL particle subclasses were reduced during apheresis (large 68.0 ± 17.5 to 16.3 ± 2.1 mg/dL, (p = 0.03), intermediate 38.3 ± 0.6 to 5.0 ± 3.5 mg/dL (p = 0.004) and small 5.0 ± 2.6 to 0.2 ± 0.1 mg/dL (p = 0.08)). There were non-significant reductions in the LDL subclasses during evolocumab treatment. There were non-significant reductions in subclasses of HDL particles during apheresis, and no changes during evolocumab treatment. CEC was unchanged throughout the study, while the SAA1/PON1 ratio was unchanged during apheresis but decreased during evolocumab treatment. In conclusion, there were significant reductions in large and intermediate size LDL particles during apheresis, and a non-significant reduction in small LDL particles. There were only non-significant reductions in the LDL subclasses during evolocumab treatment.

show abstract

Section: Cec Pon1 Activity and Saa1contrasting

confidence: 81%

Lipoprotein apheresis affects lipoprotein particle subclasses more efficiently compared to the PCSK9 inhibitor evolocumab, a pilot study

Lappegård

Kjellmo

Ljunggren

et al. 2018

Transfusion and Apheresis Science

View full text Add to dashboard Cite

show abstract

“…Pharmacological intervention to deplete SAP is shown to delay amyloid deposition in mice , and reduces proteinuria in human renal amyloidosis , demonstrating its key role in amyloid deposition. Although LDL‐A has been reported to remove SAP, serum levels immediately go back to the baseline after the treatment, indicating that LDL‐A does not effectively remove tissue SAP . This may explain the limited efficacy of LDL‐A in non‐responders.…”

Section: Discussionmentioning

confidence: 96%

“…Our data are also important in that they point to the pathological significance of SAP and APOE in nephrotic syndrome. Previous studies have shown the adsorption of these proteins to the dextran‐sulfate column . APOE is a multifunctional apolipoprotein primarily mediating lipid metabolism.…”

Section: Discussionmentioning

confidence: 99%

Proteomics Approach Identifies Factors Associated With the Response to Low‐Density Lipoprotein Apheresis Therapy in Patients With Steroid‐Resistant Nephrotic Syndrome

Kuribayashi-Okuma¹,

Shibata²,

Arai³

et al. 2016

Ther Apher Dial

View full text Add to dashboard Cite

Low-density lipoprotein apheresis (LDL-A) has been shown to reduce proteinuria in a subgroup of nephrotic syndrome patients refractory to immunosuppressive therapy. Factors influencing the efficacy of LDL-A in nephrotic syndrome are completely unknown. Using a proteomics approach, we aimed to identify biological markers that predict the response to LDL-A in patients with steroid-resistant nephrotic syndrome (SRNS). Identification of plasma proteins bound to the dextran-sulfate column at the first session of LDL-A was determined by mass spectrometry. To investigate biological factors associated with the response to LDL-A, we compared profiles of column-bound proteins between responders (defined by more than 50% reduction of proteinuria after the treatment) and non-responders by 2-dimensional gel electrophoresis (2-DE) coupled to mass spectrometry in seven patients with SRNS. Evaluation of proteins adsorbed to LDL-A column in patients with SRNS revealed the identity of 62 proteins, which included apolipoproteins, complement components, and serum amyloid P-component (SAP). Comparative analysis of the column-bound proteins between responders and non-responders by 2-DE demonstrated that apolipoprotein E (APOE) and SAP levels were increased in non-responders as compared with responders. These results were confirmed by western blotting. Moreover, serum levels of APOE and SAP were significantly higher in the non-responder group than in the responder group by ELISA. Our data provide comprehensive analysis of proteins adsorbed by LDL-A in SRNS, and demonstrate that the serum levels of APOE and SAP may be used to predict the response to LDL-A in these patients.

show abstract

Lipoprotein-apheresis: Austrian consensus on indication and performance of treatment

Derfler

Steiner

Sinzinger

2015

Wien Klin Wochenschr

View full text Add to dashboard Cite

The prevalence of familial disorders of lipid metabolism in Europe is higher than believed so far. In severely affected patients in whom conventional combined lipid lowering agents are insufficient to achieve target values, patients being intolerant to all the available members of the statin family as well as in patients with elevated lipoprotein(a) (100 mg/dl) and progression of atherosclerotic vascular disease, despite even normal low-density lipoproteins (LDL)-cholesterol values, lipoprotein-apheresis treatment is indicated. The Austrian Apheresis Consensus compares the inclusion criteria for patients to be treated in Austria with those from Italy, Germany, Spain, Japan, UK and the United States. The cut off level of 100 mg/dl for lipoprotein(a) is higher in Austria as compared to the aforementioned countries (50 or 60 mg/dl, respectively). The available clinical data reveal that regular weekly lipoprotein apheresis not only results in a significant lowering of the respective atherogenic lipid and lipoprotein parameters, but also in a significant decrease in clinical events and interventions. The underlying mechanisms such as non-lipid effects, side effects as well as the different available treatment principles are compared. For patients meeting the inclusion criteria, lipoprotein apheresis is a safe and effective therapy significantly reducing vascular events.

show abstract

LDL-Apheresis Removes Serum Amyloid P and A in Hypercholesterolemic Patients

Cited by 8 publications

References 13 publications

Lipoprotein apheresis affects lipoprotein particle subclasses more efficiently compared to the PCSK9 inhibitor evolocumab, a pilot study

Lipoprotein apheresis affects lipoprotein particle subclasses more efficiently compared to the PCSK9 inhibitor evolocumab, a pilot study

Proteomics Approach Identifies Factors Associated With the Response to Low‐Density Lipoprotein Apheresis Therapy in Patients With Steroid‐Resistant Nephrotic Syndrome

Lipoprotein-apheresis: Austrian consensus on indication and performance of treatment

Contact Info

Product

Resources

About